Status:
UNKNOWN
Guanfacine to Treat Borderline Personality Disorder
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggr...
Detailed Description
This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medi...
Eligibility Criteria
Inclusion
- This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.
Exclusion
- Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00358969
Start Date
July 1 2006
Last Update
August 1 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital - Mood & Personality Research Group
New York, New York, United States, 10029